Physician profile
Michael Brien Brown
NPI 1265674279
$34,030.32
in general payments reported to CMS, 2019-2025
21 companies · $21K in 2025
The $21K reported for 2025 was more than what 96% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $244 · 2021: $1,099 · 2022: $6,535 · 2023: $1,203 · 2024: $3,683 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Travel and Lodging: $6,347 · Food and Beverage: $3,055 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,250.00 |
| Travel and Lodging | $6,347.48 |
| Food and Beverage | $3,055.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24,512.51 | 2019-2025 | Proclaim, Eterna, Octrode |
| Medtronic, INC. | $4,488.44 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Ascenda |
| Painteq LLC | $2,866.36 | 2021-2024 | Painteq |
| Relievant Medsystems, INC. | $1,039.55 | 2022-2023 | Intracept |
| Si-Bone, INC. | $274.65 | 2019-2025 | |
| Medtronic USA, INC. | $259.37 | 2019 | |
| Vertos Medical, INC. | $137.56 | 2020 | |
| Tersera Therapeutics LLC | $128.03 | 2019 | |
| Boston Scientific Corporation | $71.27 | 2021-2022 | |
| Saol Therapeutics INC. | $41.45 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.73 | 2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.57 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $23.52 | 2019 | |
| Allergan, INC. | $19.57 | 2021 | |
| Pfizer INC. | $17.14 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $17.05 | 2021 | |
| Biodelivery Sciences International, INC. | $16.63 | 2019 | |
| Vertiflex, INC. | $13.06 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.04 | 2019 | |
| Sentynl Therapeutics, INC. | $12.42 | 2019 | |
| Mdd US Operations, LLC | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.